People who take the weight-loss drug rimonabant may face heightened risks for severe depression and anxiety, Danish researchers report.
The finding follows a recommendation by a U.S. Food and Drug Administration panel in June…
Abstract
Introduction: Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term adverse outcomes.
Aims: To review the evidence on rimonabant, a novel CB1 receptor antagonist, for the treatment of obese and overw…
MUNICH — The investigational drug rimonabant, first in a new class of agents known as selective endocannabinoid type 1 receptor blockers, is looking more and more like the real deal: a potential blockbuster drug causing sustained weight loss in the obese, reversal of t…
SAN DIEGO — The investigational drug rimonabant produces highly significant cardiovascular and metabolic benefit in patients with type 2 diabetes, Andre Scheen, M.D., reported at the annual scientific sessions of the American Diabetes Association.
Earlier this year, Sanofi-Aventis filed for U.S. and European licensure of the selective endocannabinoid type 1–receptor blocker, based on data from a series of phase III trials involving more t…
